undamentalytics Newsletter
Sign in

Vivos Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Vivos Therapeutics, Inc. had total assets of $25.2m, total liabilities of $26.7m and shareholders' equity of −$1.5m. It held $2.0m in cash against $19.3m of debt: net debt of $17.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents0182442622
Receivables11100021
Total current assets2202752744
Goodwill33333399
Total assets825341411152524
Accounts payable11112123
Deferred revenue (current)33232101
Total current liabilities9887751820
Short-term debt411———88
Long-term debt401—1100
Total debt411—111916
Total liabilities98891072728
Shareholders' equity−31726508−1−4
Non-controlling interests and other (assets − liabilities − equity)1———————
Net debt (negative = net cash)3−17−23−4−0−51714
Shares outstanding———7m9m—9m15m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NEPH vs VVOSVVOS vs ZJYLSNOA vs VVOSBDMD vs VVOS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Vivos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivos Therapeutics, Inc.